In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Roche, Seaside collaborate on Fragile X and autism disorders; terminated
11 Sep 2014
Seaside Therapeutics LLC (neurodevelopmental diseases caused by single-gene mutations) has exclusively licensed Roche patents related to metabotropic glutamate receptor subtype 5 (mGluR5) antagonists for brain development disorders. The Big Pharma also received an option on Seaside’s gamma-aminobutyric acid type B (GABA-B) agonist STX209 (arbaclofen), in Phase III for Fragile X syndrome (FXS) and Phase II for autism spectrum disorders (ASD).
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?